Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 17/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25927823 | 0.98 | MMP2 (0.54) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL25927798 | 0.95 | HTR7 (0.51) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL25927782 | 0.92 | HTR7 (0.49) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL28140642 | 0.91 | MMP2 (0.50) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL13233884 | 0.88 | PDK2 (0.53) | HTR7PDK2PDK4 | |
| SCHEMBL25927790 | 0.87 | MMP2 (0.47) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL31070188 | 0.86 | MMP2 (0.45) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL25408677 | 0.84 | MMP2 (0.47) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL28078068 | 0.84 | MMP2 (0.47) | MMP2MMP9MMP8MMP13HTR7 | |
| SCHEMBL250063 | 0.82 | GAA (0.54) | MMP2MMP9PDK2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | MMP2 1794/4885MMP9 2687/4885MMP8 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.